Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19

University of Copenhagen logo

University of Copenhagen

Status

Completed

Conditions

Type 2 Diabetes Mellitus

Treatments

Other: Placebo
Other: GIP
Other: GLP-2

Study type

Interventional

Funder types

Other

Identifiers

NCT03867656
KS-4-Diabetes-19

Details and patient eligibility

About

Both GLP-2 and GIP reduce the bone resorption (measured as CTX) in healthy persons. In this study, we will investigate wether GLP-2 and GIP is reducing CTX in persons with type 2 diabetes.

Enrollment

10 patients

Sex

Male

Ages

25 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male
  • Age 25 to 70 years old.
  • Type 2 diabetes.
  • In Metformin or sulfonylureas

Exclusion criteria

  • Treatment with other antidiabetics
  • Osteopososis or gastrointestinal disease
  • Smoking
  • Long term steroid treatment
  • Weight change more than 3 kg within the last 3 months.
  • Overweight or intestinal surgery

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

10 participants in 3 patient groups, including a placebo group

GLP-2
Experimental group
Description:
Glucagon-like peptide 2
Treatment:
Other: GLP-2
GIP
Experimental group
Description:
Glucose-dependent insulinotropic polypeptide
Treatment:
Other: GIP
Placebo
Placebo Comparator group
Description:
Saline
Treatment:
Other: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems